Lung cancer: open trials in Denmark

• NCT06793215

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Hoffmann-La Roche

  Aarhus Universitetshospital, Aarhus N · Herlev Hospital, Afdeling for Kræftbehandling, Center for Kræftforskning, Klinisk Forskningsenhed, Herlev · Rigshospitalet, København Ø · Sjællands Universitetshospital, Køge;Onkologisk Afdeling, Køge · Onkologisk Ambulatorium - Sønderborg, Sønderborg

  Registry updated 2026-11-05

• NCT07144280

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · Pfizer

  Aarhus University Hospital, Aarhus N · Rigshospitalet, Copenhagen Oe · Herlev Hospital, Herlev · Region Sjaelland, Koege · Odense University Hospital, Odense C

  Registry updated 2026-11-05

• NCT07563738

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  Trial Treatment · Phase 1/2 · Orion Corporation, Orion Pharma

  Aalborg Universitets hospital, Aalborg · Rigshospitalet University, Copenhagen

  Registry updated 2026-11-05

• NCT06119581

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · Eli Lilly and Company

  Region Sjaelland, Roskilde

  Registry updated 2026-11-04

• NCT06452277

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 3 · Bayer

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-11-04

• NCT03340506

  Dabrafenib and/or Trametinib Rollover Study

  Trial Treatment · Phase 4 · Novartis Pharmaceuticals

  Rigshospitalet, Copenhagen Oe

  Registry updated 2026-11-03

• NCT06170788

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Aalborg University Hospital, Aalborg · Region Midtjylland, Herning · Odense University Hospital, Odense C

  Registry updated 2026-11-03

• NCT07195695

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  Trial Treatment · Phase 3 · Boehringer Ingelheim

  Region Sjaelland, Roskilde

  Registry updated 2026-11-02

• NCT04613596

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.

  Sygehus Soenderjylland Soenderborg, Soenderborg · Sygehus Lillebaelt - Vejle Sygehus, Vejle

  Registry updated 2026-10-30

• NCT05067283

  Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors

  Trial Treatment · Phase 1 · Merck Sharp & Dohme LLC

  Odense University Hospital, Odense C

  Registry updated 2026-10-30

• NCT04928846

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · AbbVie

  Odense University Hospital, Odense C · Region Sjaelland, Roskilde

  Registry updated 2026-10-29

• NCT07185958

  Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy

  Research · Aalborg University Hospital

  Aalborg University Hospital, Aalborg · Copenhagen University Hospital Herlev and Gentofte, Herlev · Odense University Hospital, Odense

  Registry updated 2026-10-29

• NCT06914128

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  Trial Treatment · Phase 1/2 · Bayer

  Rigshospitalet Copenhagen University Hospital | Oncology Department, Copenhagen · Odense University Hospital | Svendborg Sygehus - Oncology Department, Odense

  Registry updated 2026-10-28

• NCT05920356

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Trial Treatment · Phase 3 · Amgen

  Region Midtjylland, Herning · Lillebaelt Hospital, Vejle

  Registry updated 2026-10-23

• NCT06561386

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe · Sygehus Soenderjylland Soenderborg, Soenderborg

  Registry updated 2026-10-23

• NCT07063745

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  Trial Treatment · Phase 2/3 · Bristol-Myers Squibb

  Copenhagen University Hospital, Copenhagen Oe

  Registry updated 2026-10-23

• NCT07432802

  Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer

  Trial Treatment · Aarhus University Hospital

  Aalborg University Hospital, Aalborg · Aarhus University Hospital, Aarhus N · Rigshospitalet, Copenhagen · Odense University Hospital, Odense

  Registry updated 2026-10-23

• 2025-522818-23-00

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Zai Lab (US) LLC

  Region Hovedstaden, Herlev · Lillebaelt Hospital, Vejle

  Registry updated 2026-10-19

• NCT06162221

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  Trial Treatment · Phase 1/2 · Revolution Medicines, Inc.

  Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-10-19

• NCT05786924

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  Trial Treatment · Phase 1/2 · Institut de Recherches Internationales Servier

  Center for Cancer and Organ Diseases - Rigshospitalet, Copenhagen

  Registry updated 2026-10-13

• NCT07261631

  Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

  Trial Treatment · Phase 1 · Novartis Pharmaceuticals

  Odense C

  Registry updated 2026-10-09

• NCT06765109

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  Trial Treatment · Phase 3 · Nuvalent Inc.

  Region Midtjylland, Aarhus N · Region Hovedstaden, Herlev · Odense University Hospital, Odense C

  Registry updated 2026-09-30

• NCT07848815

  Risk-Based Lung Cancer Detection in COPD Patients

  Trial Treatment · Vejle Hospital

  Vejle Hospital, University Hospital of Southern Denmark, Vejle

  Registry updated 2026-09-30

• 2025-524439-38-00

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  Trial Treatment · Phase 2 · Oslo Universitetssykehus HF

  Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Region Hovedstaden, Herlev · Region Sjaelland, Koege · Odense University Hospital, Odense C

  Registry updated 2026-09-28

• NCT06758401

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  Trial Treatment · Phase 3 · Pfizer

  Rigshospitalet, Copenhagen Oe · Region Sjaelland, Roskilde

  Registry updated 2026-09-25

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error